Highly selected patient population with normal renal functions has benefitted from trimodality treatments in the form of transurethral resection of bladder tumour (TURBT) followed by chemotherapy and concurrent chemoradiation4,5.
The remaining 16 patients had bladder lesions seen on cystoscopy and underwent a biopsy and/or TURBT. Three of these patients had benign features on pathology (urachal remnant, amyloidosis, and inflammation) and the remaining 13 (0.4%) had stage Ta urothelial carcinoma (Table 2).
We compared the results of 58 patients who underwent TURBT for NMIBC and who received intracavitary BCG therapy or intracavitary therapy with interferon-a 2A at Gaziosmanpasa Taksim Training and Research Hospital Urology Clinic of Health Sciences University between 1992 and 1996.
Her medical history included right breast invasive ductal carcinoma with bilateral mastectomies in 2015, recently diagnosed bladder cancer with TURBT and intravesical mitomycin C instillation three days prior to current presentation, type 2 diabetes mellitus, hypertension, obstructive sleep apnea, chronic obstructive pulmonary disease, and prothrombin G20210A mutation.
Recently, we experienced a case of early stage bladder carcinosarcoma in late-onset recurrence after initial urothelial carcinoma treated with transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy for long-term.
There has been a delineation between "TURBT" syndrome with the absorption of large volume of free water across the peritoneal membrane and "TURP" syndrome with its immediate consequences of intravascular overload.